SMS Pharmaceuticals Ltd (NSE: SMSPHARMA, BSE: 532815) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹3,883 Cr, it ranks #926 by market cap among the 6,189 Indian listed companies on FinBizNet, and #18 of 63 in Pharmaceuticals. At ₹414.60 (as of 26 Oct 2026), the share price is 16.1% below its 52-week high of ₹494.45 and 53.5% above its 52-week low of ₹270.10. The share price is up 42.0% over one year and up 8.8% over three months.
| Current Price | ₹414.60 |
|---|---|
| Market Cap | ₹3,883 Cr |
| NSE Symbol | SMSPHARMA |
| BSE Code | 532815 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 37.2 |
| Return on Equity | 14.31% |
| Return on Assets | 6.65% |
| 52-Week Range | ₹270.10 – ₹494.45 |
| 1-Year Price Change | +42.0% |
| 3-Month Price Change | +8.8% |
| Beta (1Y) | 0.54 |
| Dividend Yield | 0.10% |
| Headquarters | Hyderabad, Telangana |
| Website | www.smslife.in |
| Revenue | ₹207 Cr |
|---|---|
| Net Profit | ₹20 Cr |
| Net Margin | 9.8% |
| EPS (Basic) | ₹2.23 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
1. Pharmaceutical-This segment researches, develops, manufactures, buys, imports, sells, and exports active pharmaceutical ingredients and its intermediates.
1. Pharmaceutical Products Including Ingredients and Intermediaries-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| SMS Pharmaceuticals Ltd | ₹3,883 Cr | 37.2 | 14.31% | ₹207 Cr | +42.0% |
Listed by market capitalisation. Ratios are shown for context only.
SMS Pharmaceuticals Ltd is trading at ₹414.60, with a market capitalisation of ₹3,883 Cr.
SMS Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
SMS Pharmaceuticals Ltd has a P/E of 37.2 and a return on equity of 14.31%.
SMS Pharmaceuticals Ltd is listed on the NSE under the symbol SMSPHARMA and on the BSE under the scrip code 532815.
SMS Pharmaceuticals Ltd's share price is up 42.0% over one year and up 8.8% over three months. Its 52-week range is ₹270.10 to ₹494.45.
In Q1 FY27, SMS Pharmaceuticals Ltd reported revenue of ₹207 Cr and net profit of ₹20 Cr, with basic EPS of ₹2.23 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.